KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Adaptive Biotechnologies (ADPT) Shares Outstanding (Weighted Average): 2018-2025

Historic Shares Outstanding (Weighted Average) for Adaptive Biotechnologies (ADPT) over the last 7 years, with Sep 2025 value amounting to $152.3 million.

  • Adaptive Biotechnologies' Shares Outstanding (Weighted Average) rose 3.26% to $152.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $152.3 million, marking a year-over-year increase of 3.26%. This contributed to the annual value of $147.6 million for FY2024, which is 1.94% up from last year.
  • Latest data reveals that Adaptive Biotechnologies reported Shares Outstanding (Weighted Average) of $152.3 million as of Q3 2025, which was up 0.24% from $151.9 million recorded in Q2 2025.
  • Adaptive Biotechnologies' Shares Outstanding (Weighted Average)'s 5-year high stood at $152.3 million during Q3 2025, with a 5-year trough of $139.2 million in Q1 2021.
  • Moreover, its 3-year median value for Shares Outstanding (Weighted Average) was $147.4 million (2024), whereas its average is $147.0 million.
  • Data for Adaptive Biotechnologies' Shares Outstanding (Weighted Average) shows a peak YoY increased of 10.58% (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows Adaptive Biotechnologies' Shares Outstanding (Weighted Average) stood at $141.1 million in 2021, then increased by 1.33% to $143.0 million in 2022, then rose by 1.23% to $144.8 million in 2023, then grew by 1.94% to $147.6 million in 2024, then grew by 3.26% to $152.3 million in 2025.
  • Its last three reported values are $152.3 million in Q3 2025, $151.9 million for Q2 2025, and $148.6 million during Q1 2025.